Drug Guide
Amitriptyline Hydrochloride; Chlordiazepoxide
Classification
Therapeutic: Antidepressant and Anxiolytic
Pharmacological: Tricyclic antidepressant and Benzodiazepine
FDA Approved Indications
- Major depressive disorder
- Anxiety disorders (off-label use in some cases)
Mechanism of Action
Amitriptyline inhibits reuptake of norepinephrine and serotonin, increasing their levels in the CNS; Chlordiazepoxide enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Dosage and Administration
Adult: Typically, start at a low dose and titrate based on response and tolerability. Example: 25 mg of amitriptyline at bedtime, with adjustments as needed.
Pediatric: Not generally recommended for children due to safety profile.
Geriatric: Start at lower doses due to increased sensitivity and risk of side effects.
Renal Impairment: Use caution; consider dose adjustments.
Hepatic Impairment: Use caution; start at lower doses and monitor closely.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed; crosses the blood-brain barrier.
Metabolism: Hepatic via CYP450 enzymes, mainly CYP2D6.
Excretion: Primarily in urine.
Half Life: Amitriptyline: approximately 10-28 hours; Chlordiazepoxide: approximately 24-48 hours, with active metabolites extending activity.
Contraindications
- Hypersensitivity to the components.
- Recent use of MAO inhibitors.
- Glaucoma, urinary retention, severe hepatic impairment.
Precautions
- Use cautiously in elderly, patients with cardiac arrhythmias, seizure disorders, or history of substance abuse.
- Risk of dependency with benzodiazepines.
- Monitor for signs of serotonin syndrome, especially if combined with other serotonergic drugs.
Adverse Reactions - Common
- Sedation (Occasional to frequent)
- Dry mouth (Frequent)
- Dizziness (Common)
- Weight gain (Less common)
Adverse Reactions - Serious
- Serotonin syndrome (Rare)
- QT prolongation and arrhythmias (Rare)
- Seizures (Rare)
- Dependence and withdrawal symptoms (Rare)
Drug-Drug Interactions
- Other CNS depressants, alcohol, MAO inhibitors, other serotonergic agents.
Drug-Food Interactions
- Alcohol (enhances sedative effect).
Drug-Herb Interactions
- St. John's Wort (risk of serotonin syndrome).
Nursing Implications
Assessment: Monitor mental status, suicidal ideation, and response to therapy; assess for adverse effects such as drowsiness, dizziness, and changes in mood.
Diagnoses:
- Risk for injury related to sedation or orthostatic hypotension.
- Risk for falls in elderly.
Implementation: Administer as prescribed, usually at bedtime for sedative effects. Monitor vital signs, and assess for therapeutic effectiveness.
Evaluation: Observe for reduction in depressive symptoms and anxiety, and monitor for adverse reactions.
Patient/Family Teaching
- Avoid alcohol and CNS depressants.
- Do not discontinue abruptly to prevent withdrawal symptoms.
- Report unusual changes in mood, behavior, or signs of serotonin syndrome.
- Use caution when operating machinery.
Special Considerations
Black Box Warnings:
- Because of the risk of suicidal thoughts and behaviors in children, adolescents, and young adults with depression, close monitoring is essential.
Genetic Factors: CYP2D6 poor metabolizers may experience increased plasma levels, leading to greater side effects.
Lab Test Interference: May affect thyroid function tests or ECG readings.
Overdose Management
Signs/Symptoms: Confusion, agitation, hallucinations, seizures, coma, cardiac arrhythmias, hypotension.
Treatment: Supportive care, activated charcoal if recent ingestion, seizure control, cardiac monitoring, and specific antidotes for benzodiazepine overdose if necessary.
Storage and Handling
Storage: Store at room temperature, protected from light and moisture.
Stability: Stable when stored properly, check expiration date regularly.